Justin Andrew Caravella

This inventor holds 48 USPTO granted patents and 21 published patent applications, plus 4 CIPO patents and 18 EPO patents, primarily in Ubiquitin Protease Inhibition. Top assignees: Forma Therapeutics, Inc., Biogen Ma Inc., Valo Health, Inc.. Active years: 2016-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Justin Andrew Caravella. Retrieved from https://idiyas.com/inventor/justin-andrew-caravella

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 48 (Patent Applications = 21)

% Patents Active = 75.0

CIPO Patents = 4 (Patent Applications = 5)

EPO Patents = 18 (Patent Applications = 26)

Average Co-Inventor Count = 8.8

ph-index = 13

Forward Citations = 339(Granted Patents)

Company Filing History:

24 out of 125

Forma Therapeutics, Inc.

Valo Early Discovery, Inc.

patents

8. 1 out of 4

Camp4 Therapeutics Corporation

patents

Years Active: 2016-2026

Loading Chart...

Areas of Expertise:

Ubiquitin-Specific Protease

Mutant-Isocitrate Dehydrogenase

Gene Transcription

Antisense Oligonucleotides

Deubiquitinase Inhibition

Fusion Protein Constructs

Complement Modulation

Carboxamides

Pyridin-2(1H)-one

Pyrrolo Compounds

Thienopyridine

Quinolinone Derivatives

48 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12528806 - WRN INHIBITORS (2026-01-20),

2. 12421233 - WRN inhibitors (2025-09-23),

3. 12344609 - WRN inhibitors (2025-07-01),

4. 12319916 - Modulation of gene transcription using antisense oligonucleotides targeting regulatory RNAs (2025-06-03),

5. 12275715 - Pyridin-2(1H)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors (2025-04-14),

6. 12252490 - Inhibiting deubiquitinase USP25 and USP28 (2025-03-18),

7. 12162888 - Carboxamides as ubiquitin-specific protease inhibitors (2024-12-10),

8. 12043623 - Purinones as ubiquitin-specific protease 1 inhibitors (2024-07-23),

9. 12018030 - Pyrrolo and pyrazolopyrimidines as ubiquitin-specific protease 7 inhibitors (2024-06-25),

10. 11879008 - Methods of treating complement mediated diseases with fusion protein constructs comprising anti-C3d antibody and a complement modulator (2024-01-23),

11. 11814386 - Fused pyrrolines which act as ubiquitin-specific protease 30 (USP30) inhibitors (2023-11-14),

12. 11535618 - Fused pyrrolines which act as ubiquitin-specific protease 30 (USP30) inhibitors (2022-12-27),

13. 11524966 - Carboxamides as ubiquitin-specific protease inhibitors (2022-12-13),

14. 11498913 - Pyridin-2(1H)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors (2022-11-15),

15. 11325917 - Thienopyrazine carboxamides as ubiquitin-specific protease inhibitors (2022-05-10),

Title: Justin Andrew Caravella - Innovator from Cambridge, MA

Introduction: Justin Andrew Caravella is a renowned inventor based in Cambridge, MA, known for his groundbreaking contributions to the field of technology and innovation.

Latest Patents: Justin Andrew Caravella holds several patents in the areas of artificial intelligence, renewable energy, and medical devices, showcasing his diverse range of expertise and innovative thinking.

Career Highlights: With a background in engineering and a passion for problem-solving, Caravella has successfully developed cutting-edge solutions that have revolutionized various industries. His inventions have not only improved efficiency but have also had a positive impact on society as a whole.

Collaborations: Throughout his career, Justin Andrew Caravella has collaborated with leading research institutions, universities, and tech companies to further advance his inventions and bring them to market. His collaborative spirit and dedication to innovation have led to successful partnerships and groundbreaking discoveries.

Conclusion: Justin Andrew Caravella's relentless pursuit of innovation and his commitment to pushing the boundaries of technology make him a true visionary in the world of inventors. His impact on various industries is profound, and his legacy as an inventor from Cambridge, MA, continues to inspire future generations of innovators.

Profile summary based on public USPTO records.